FDA Determines Regulatory Review Period for Nextstellis Patent Extension

Summary

The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for Nextstellis, a human drug product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).